Compare Biogen Inc (BIIB) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Standard Lithium Ltd — how do they compare? Biogen Inc trades at $193.38 (market cap $28.34B), while Standard Lithium Ltd trades at $2.29 (market cap $577.14M). The key difference: Biogen Inc is far larger — about 49.1× Standard Lithium Ltd's market cap, and Biogen Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| BIIB | SLI | |
|---|---|---|
Market Cap | $28.34B | $577.14M |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $5.65 |
52-Week Low | $122.68 | $2.29 |
Enterprise Value | $30.62B | $436.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
SLI trades at $2.29, down 6.91% today, with a bearish technical trend but oversold RSI readings. The company reported a net loss of $48.40 million in 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus is unanimously bullish with 3 buy ratings.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include cash burn and execution delays, but long-term upside exists if production targets are met. Investors should weigh high operational losses against strong institutional backing and strategic partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
